Long-term Treatment Effects of Frexalimab on NfL, CXCL13, and Brain Volume Loss in Relapsing Multiple Sclerosis (EAN 2026) - Jun 12, 2026 - Abstract #EPO-0790; Pres time: Jun 29, 2026; 01:40 PM - 01:45 PM; Location: B5; P2 | "Three years of frexalimab treatment markedly reduced NfL and CXCL13, and limited BVL in pwRMS. These data demonstrate its effects on neuroinflammation and neurodegeneration, supporting further investigation in RMS and non-relapsing secondary progressive MS."
CNS Disorders • Inflammation • Multiple Sclerosis • CD40LG • CXCL13 • NEFL • Plasma NfL
|
|
C. Granziera 1; P. Vermersch 2; B. Djukic 3; S. S. Geertsen 3; A. T. Shafer 3; P. Truffinet 4; G. Giovannoni 5
|